Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3000 El Camino Real, Bldg 4, Ste 200 PALO ALTO CA 94306 |
Tel: | 1-678-5706791 |
Website: | https://180lifesciences.com |
IR: | See website |
Key People | ||
Lawrence Steinman Co-Executive Chairman of the Board | James N. Woody Chief Executive Officer, Director | Ozan Pamir Chief Financial Officer, Company Secretary | Jonathan Rothbard Chief Scientific Officer |
Business Overview |
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor (anti-TNF). SCAs platform is focused on drugs which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). a7nAChR platform is focused on alpha 7 nicotinic acetylcholine receptor (a7nAChR). It is conducting clinical trials only for certain indications under the anti-TNF platform. The Company is undertaking preclinical research and development activities for the SCA platform. |
Financial Overview |
For the fiscal year ended 31 December 2023, 180 Life Sciences Corp revenues was not reported. Net loss decreased 49% to $19.9M. Lower net loss reflects Loss on goodwill impairment decrease from $33.5M (expense) to $0K, General and administrative decrease of 31% to $10.5M (expense), Gain on settlement of accrued liability increase from $0K to $204K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$387.18 to -$52.59. |